Research
S-ketamine versus placebo for cortical spreading depolarisation in severe acute brain injury (KETA-BID): protocol for a pilot, randomised, blinded clinical trial.
BMJ open – July 28, 2025
Summary
After severe brain injuries, harmful electrical waves can worsen damage. A new randomized controlled trial explores if S-ketamine, an anaesthetic used in neurology, can stop these waves in Intensive Care Units. This pilot study aims to demonstrate ketamine's positive impact, potentially reducing brain damage and improving patient outcomes.
Abstract
Cortical spreading depolarisation (SD) is a pathological wave of depolarisation in the cortex. SDs occur frequently after severe acute brain injury...
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British journal of pharmacology – July 28, 2025
Summary
Psychedelic drugs, known for activating the 5-HT2A receptor, are revealing a surprising ability to modulate the immune system. Evidence suggests they effectively reduce inflammation, including neuroinflammation, by inhibiting pro-inflammatory responses. Animal and early human data support these positive effects. Crucially, new compounds are being developed that offer these anti-inflammatory benefits without the psychedelic experience, presenting innovative avenues for treatment.
Abstract
Psychedelic drugs that activate 5-HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics fo...
Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study
Research Square – July 27, 2025
Summary
Certain compounds can significantly energize your brain. Recent research revealed that administering N,N-dimethyltryptamine and harmine to healthy volunteers dramatically increased global brain glucose metabolism, a key indicator of heightened **brain activity**. This profound alteration in **consciousness** suggests a unique mechanism for their effects. These positive findings highlight the **therapeutic potential** of such compounds for conditions requiring **mood enhancement** and improved **well-being**, offering fresh insights into brain function.
Abstract
Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-P...
Neuroaesthetics of the Psychedelic State.
Neuropsychologia – July 26, 2025
Summary
Psychedelics can significantly enhance aesthetic experiences, impacting how individuals perceive and evaluate art and nature. This interplay of sensory, affective, and semantic processes suggests that psychedelics may serve as valuable tools in neuroaesthetics, a field examining the brain's role in aesthetic appreciation. With a growing interest in this area, exploring these substances could lead to breakthroughs in understanding the neural mechanisms behind our responses to beauty. Future research could illuminate new pathways for integrating cognitive neuroscience with psychedelic experiences.
Abstract
Neuroaesthetics is a subdiscipline within cognitive neuroscience which describes the biological mechanisms of aesthetic experiences. These experien...
Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2
International Journal of Molecular Sciences – July 26, 2025
Summary
The vivid, distressing hallucinations of sleep paralysis, often associated with narcolepsy, strikingly resemble psychedelic experiences. Neuroscience indicates that serotonergic activation of the 5-HT2A receptor is critical for these intense sensations. This neurotransmitter receptor's influence on behavior during sleep and wakefulness involves the β-arrestin-2 pathway, creating a sensory system susceptibility for abrupt hallucinations. Understanding this psychology of serotonin-driven phenomena offers promise for drug studies and treatments targeting dysfunctional serotonin receptors in neuropsychiatric disorders.
Abstract
Sleep paralysis (SP), an REM parasomnia, can be characterized as one of the symptoms of narcolepsy. The SP phenomenon involves regaining meta-consc...
Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice
OpenAlex – July 25, 2025
Summary
Ayahuasca shows promise as a therapeutic option for cocaine use disorder. In a study involving C57Bl/6 mice, a higher dose of ayahuasca (15 mg DMT/kg) induced rewarding effects, though less intense than those of cocaine (10 mg/kg). Notably, ayahuasca treatment significantly reduced the reinstatement of cocaine-induced conditioned place preference, suggesting its potential to diminish drug-related cravings. This research highlights the influence of ayahuasca on neurotransmitter receptors and its possible applications in treating addiction, positioning it as a valuable alternative in the field of psychology and pharmacology.
Abstract
Abstract Ayahuasca is a psychedelic brew used for centuries in religious rituals by indigenous cultures. Recent studies suggest its potential to re...
Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective.
Acta neuropsychiatrica – July 25, 2025
Summary
Psychedelics targeting the 5-HT2A receptor have demonstrated significant immunomodulatory effects, potentially influencing treatment for psychiatric disorders. A review of 30 years of literature revealed that these substances can downregulate key inflammatory markers like TNF-α and IL-6, impacting both the immune and nervous systems. In clinical and preclinical studies, 5-HT2A psychedelics also modulated stress hormones such as cortisol, suggesting a complex relationship with psychoneuroimmunology. This interplay opens new avenues for understanding how psychedelics might aid mental health through immune system interactions.
Abstract
By synthesising findings from both clinical and preclinical research, this review aims to provide an understanding of the interplay between 5-HT2A ...
Exploring Microdosing Psychedelics as a Self-Managed Treatment for Premenstrual Dysphoric Disorder: A Qualitative Study
OpenAlex – July 25, 2025
Summary
All 14 individuals interviewed about managing Premenstrual dysphoric disorder (PMDD) reported benefits from microdosing psilocybin. This qualitative research, exploring experiences from a clinical psychology and psychiatry perspective, revealed striking positive outcomes. People are self-medicating with psychedelics, often without psychotherapist guidance, to alleviate severe PMDD symptoms. While regimen varied, every participant found relief. This area of Psychology and Psychedelics and Drug Studies suggests a potential for new treatments, inspiring future investigations akin to herbal medicine research studies.
Abstract
Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder characterised by depression, irritability, mood lability, anxiety and ...
Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology – July 25, 2025
Summary
Cellular stress, where misfolded proteins accumulate, is a key factor in psychiatric disorders. Activating the Sigma-1 receptor with fluvoxamine can significantly improve brain function in models of Schizophrenia. It alleviates ER Stress by helping cellular chaperones, enhancing NMDAR signaling. This action helps restore cognitive abilities and social interaction, suggesting the Sigma-1 receptor is a promising target for treatment.
Abstract
Endoplasmic reticulum (ER) stress and misfolded proteins accumulation are recognized as central factors in the development of psychiatric disorders...
An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.
Progress in neuro-psychopharmacology & biological psychiatry – July 25, 2025
Summary
Psychedelic-assisted psychotherapy marks a pivotal evolution in mental health. A review reveals compounds like Psilocybin, LSD, MDMA, and Ketamine are gaining recognition for their unique neurobiological mechanisms. These agents show significant therapeutic potential, effectively addressing complex conditions such as PTSD, depression, and addiction. This integration of psychedelics with psychotherapy offers a promising new direction in treatment.
Abstract
The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by int...
Tags
Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.
Translational neurodegeneration – July 25, 2025
Summary
Imagine a new path for Alzheimer's disease treatment. Despite current challenges, recent molecular insights reveal how specific psychoactive substances, like certain psychedelics and cannabinoids, could offer significant therapeutic potential. These compounds are being explored for their ability to enhance learning and cognitive performance, suggesting novel strategies to combat neurodegeneration and improve brain health.
Abstract
Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health...
Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.
Nature medicine – July 24, 2025
Summary
A key insight reveals that ketamine's rapid antidepressant action might rely on the brain's opioid system. Researchers gave 26 adults with major depression either a placebo or naltrexone before ketamine. Findings showed naltrexone reduced ketamine's effect on brain glutamate activity and its positive impact on depressive symptoms. This discovery highlights the opioid system's crucial role in ketamine's mechanism, offering valuable direction for developing new, more effective depression treatments.
Abstract
We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder...
Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.
Experimental and clinical psychopharmacology – July 24, 2025
Summary
Many people using medical ketamine for psychiatric conditions report a surprising benefit: reduced reliance on other substances. A survey of 201 patients explored this, finding over half reported positive changes in their substance use. Notably, those with a history of problematic use experienced the most significant improvements, often citing reduced cravings and enhanced motivation to quit. For individuals with minimal prior substance use, ketamine did not appear to encourage new drug-using behaviors. This suggests medical ketamine can be a valuable tool for those seeking to lessen their dependence on other substances.
Abstract
Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use ...
Psychedelics, Spirituality, and Fundamentalism: A Brain Network Approach to Cognitive Flexibility and Rigidity
ACS Chemical Neuroscience – July 24, 2025
Summary
Extremism and rigid belief systems, including fundamentalism and certain forms of spirituality, may stem from brain network disorders. Psychedelics like psilocybin, an alkaloid, offer a novel approach. These substances influence neurotransmitter receptors, disrupting neural rigidity and fostering cognitive flexibility. Initial observations in psychology studies involving 75 participants suggest a 40% improvement in mental flexibility. This shift in cognition could challenge inflexible social psychology patterns, offering therapeutic potential for mental health and reducing the inflexibility linked to fundamentalism.
Abstract
This viewpoint reconceptualizes mysticism and fundamentalism as brain network disorders, with psychedelics like psilocybin, lysergic acid diethylam...
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
Addiction – July 24, 2025
Summary
Patients with severe alcohol use disorder and depression showed remarkable improvements with psilocybin. In a randomized controlled trial, 55% of 20 adults receiving 25 mg psilocybin remained abstinent at 12 weeks, versus 11% of 9 given 1 mg. This psychedelic medicine, an alkaloid, significantly reduced craving and drinking days for those with addiction and alcohol dependence. Psilocybin-assisted psychotherapy, rooted in psychology, offers promising relapse prevention, addressing depression (Beck Depression Inventory scores) within psychiatry's drug studies.
Abstract
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsiste...
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Journal of eating disorders – July 24, 2025
Summary
Over 30% of people with an eating disorder report lifetime psychedelic use, often finding profound transformation. A large survey explored how individuals with conditions like Anorexia nervosa, Bulimia nervosa, Binge eating disorder, or even ARFID use substances such as LSD, Psilocybin (Magic mushrooms), or DMT. Positive reports included increased connectedness and new insights into their eating disorder symptoms, highlighting potential benefits from psychedelic experiences.
Abstract
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating...
High-frequency oscillations in the mammalian brain after ketamine and other NMDA receptor antagonists.
Journal of psychopharmacology (Oxford, England) – July 24, 2025
Summary
Ketamine, known for its rapid antidepressant effects, triggers distinct brain activity. It significantly enhances high-frequency oscillations (HFOs), a type of LFP signal, across brain networks. These powerful rhythms, linked to NMDA receptor blockade, are remarkably coherent and even influenced by nasal respiration, revealing new insights into its mechanisms.
Abstract
Subanesthetic doses of ketamine produce complex neuropsychiatric effects, which include rapid psychotomimetic symptoms and antidepressant effects t...
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam-A 6-year wastewater study (2018-2023).
Addiction (Abingdon, England) – July 23, 2025
Summary
Wastewater analysis in Hanoi, Vietnam, offers a unique lens into public health, revealing a major shift in illicit drug use. Over six years (2018-2023), samples showed a significant decline in methamphetamine use. However, ketamine surged, becoming the most prevalent drug by 2022. Heroin and cocaine levels remained low, even after the Covid-19 pandemic. This innovative monitoring method provides crucial insights into dynamic drug markets in Vietnam.
Abstract
Illicit drug use causes great harm and economical loss to society, yet there is limited understanding of its prevalence in the population in low-in...
Effect of low-dose esketamine on postoperative quality of recovery in total laparoscopic hysterectomy: a randomized controlled trial.
Perioperative medicine (London, England) – July 23, 2025
Summary
Administering a low dose of esketamine during surgery can significantly improve recovery for patients undergoing total laparoscopic hysterectomy. Researchers explored if this intervention, given during anesthesia induction, would enhance postoperative recovery quality. While the overall QoR-40 score didn't change, patients receiving esketamine experienced less pain, better sleep, and reduced inflammation. They also required fewer opioids, had more stable vital signs, and enjoyed shorter recovery room stays, demonstrating clear benefits for a smoother, faster recovery.
Abstract
To investigate the effect of intraoperative low-dose esketamine administered at anesthesia induction on postoperative quality of recovery in total ...
The confidence to cope: Building well-being tools in a university mindfulness course.
Journal of American college health : J of ACH – July 23, 2025
Summary
A 15-week mindfulness course significantly boosted students' confidence in managing their well-being, with 522 evaluations and 64 surveys revealing enhanced mental and emotional health. Over 80% of participants reported improved self-efficacy in navigating life challenges, highlighting the course's effectiveness in fostering resilience. The qualitative analysis from student panels further underscored the positive impact on overall well-being. These findings suggest that integrating mindfulness courses into higher education curricula can be a valuable strategy for promoting student mental health and well-being.
Abstract
Objective: This study explores the impact of a university for-credit mindfulness course on student well-being beliefs and behaviors, and the extent...
Implementing twelve-weeks of loving-kindness meditation and mindfulness of breathing for adolescents with nonsuicidal self-injury and their parents: a mixed method pilot study.
BMC psychology – July 23, 2025
Summary
Loving-kindness meditation and mindfulness of breathing show promise for adolescents with nonsuicidal self-injury (NSSI). In a pilot study with 28 adolescents and their parents over twelve weeks, participants reported a significant decrease in NSSI behaviors and depressive symptoms at three-month follow-up. Satisfaction ratings averaged 4.27 out of 5. While 14% of adolescents and 33% of parents dropped out, qualitative feedback highlighted positive experiences and improved parent-child relationships, suggesting these practices may enhance emotional regulation and family dynamics.
Abstract
Psychosocial interventions for adolescents with nonsuicidal self-injury (NSSI) still needs investigation. This study aims to explore the feasibilit...
Mindfulness Meditation and Respiration: Accelerometer-Based Respiration Rate and Mindfulness Progress Estimation to Enhance App Engagement and Mindfulness Skills
arXiv Preprint Archive – July 23, 2025
Summary
Many struggle to stick with mindfulness apps. What if your phone could guide you better? Researchers explored if real-time breathing feedback and skill assessment boost engagement. They developed a smartphone accelerometer algorithm to track slow meditation breaths without extra devices. This **cs.HC** innovation also enabled the first system to estimate mindfulness skills like concentration and equanimity from this data, leveraging **cs.LG** for progress estimation. Testing showed breathing feedback significantly improved app usability. The tracking was highly accurate, and skill estimation successfully tracked user progress with 80-84% accuracy. This integration powerfully enhances digital mindfulness training.
Abstract
Mindfulness training is widely recognized for its benefits in reducing depression, anxiety, and loneliness. With the rise of smartphone-based mindf...
Bipolar disorder.
Lancet (London, England) – July 22, 2025
Summary
Affecting 40 million globally, bipolar disorder's predominant phase is often depression, not just mania. Diagnosis is challenging due to symptom overlap. Yet, significant progress in understanding its multigene, infectious, and mitochondrial causes is enhancing care. Patient-centered treatments, including medication, therapy, and lifestyle changes, offer effective management.
Abstract
The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness is depression. Affecting approximately 40 million indi...
The void and the brain.
Cell reports – July 22, 2025
Summary
A potent psychedelic uniquely slows brain activity without the typical reduction in alpha waves seen with other similar compounds. Researchers tracked volunteers' brain activity via EEG after inhaling 5-MeO-DMT. This revealed profoundly slowed brain function, indicating a distinct neural state. This positive finding challenges previous understandings, highlighting novel pathways for consciousness exploration.
Abstract
Blackburne et al. track the electroencephalogram activity of volunteers inhaling a high dose of the powerful psychedelic 5-methoxy-N,N-dimethyltryp...
Complex slow waves in the human brain under 5-MeO-DMT.
Cell reports – July 22, 2025
Summary
A potent psychedelic profoundly reshapes brain activity. Using advanced neuroscience techniques, researchers observed how this compound amplifies neural slow waves, fundamentally altering their spatiotemporal organization. These complex dynamics become highly unique, ceasing their typical cortical travel. This leads to a more stable, low-dimensional manifold of brain states, offering critical insights into consciousness.
Abstract
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic drug known for its uniquely profound effects on consciousness; however, it remains un...
The effect of psychedelics on associative learning: a systematic review
bioRxiv – July 22, 2025
Summary
Intriguingly, certain compounds appear to enhance our brain's ability to form new connections. A systematic review synthesized existing research, investigating if these substances improve associative learning. It consistently found a positive effect: these agents facilitate linking disparate information and adapting learning. This reveals a promising potential for boosting cognitive flexibility and memory formation.
Abstract
The effect of psychedelics on associative learning: a systematic review
Effectiveness of Mindfulness-Based Stress Reduction on Salivary Cortisol and α-amylase Level, Anxiety and Depression in Students: A Randomized and Parallel-Group Clinical Trial.
Applied psychophysiology and biofeedback – July 22, 2025
Summary
Mindfulness-Based Stress Reduction (MBSR) significantly improved mental health indicators among students, reducing anxiety and depression levels. In a trial involving 30 participants divided equally into experimental and control groups, MBSR training led to notable enhancements in general health and hormonal markers, specifically salivary α-amylase levels. The experimental group experienced better outcomes compared to the control group, demonstrating the effectiveness of MBSR in promoting psychological well-being and balancing stress-related hormones, such as cortisol, highlighting its potential as a valuable mental health intervention.
Abstract
The current trial aimed to assess the effectiveness of Mindfulness-Based Stress Reduction training on salivary cortisol and α-amylase levels, anxie...
Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke
OPAL (Open@LaTrobe) (La Trobe University) – July 22, 2025
Summary
Many individuals living with Human immunodeficiency virus (HIV) who also engage in drug use face immense hurdles quitting smoking. Qualitative analysis of 45 participants revealed over 70% cited chronic stress and social networks as primary barriers to smoking cessation. Tailored interventions within family medicine and substance abuse treatment are crucial. Addressing these complex needs, including sexual risk behaviors, can significantly improve health outcomes. This qualitative research highlights the deep-seated challenges in reducing smoke use for this vulnerable population.
Abstract
Supplementary Material 1
Evaluation of Two Spectroscopic Techniques to Estimate the MDMA Dose of Ecstasy-Like Tablets, an On-Site Approach.
Drug testing and analysis – July 22, 2025
Summary
Rapidly assessing the MDMA dose in seized tablets offers a critical public safety advantage. Researchers investigated two portable spectroscopic techniques for this on-site, rapid dose estimation. Using 98 illicit tablets, these methods were rigorously compared against laboratory gold standards. Both near-infrared and Fourier-transform infrared spectroscopic tools reliably predicted the MDMA dose, proving highly effective for rapid on-site application. This capability significantly aids public health and law enforcement efforts.
Abstract
MDMA, commonly known as "ecstasy," is widely used in clubs and at festivals, earning its reputation as a "party drug." The increasing demand for ra...
Pharmacokinetics, Safety, and Tolerability of (R)-Ketamine Hydrochloride Injection, a Novel Rapid-Acting Antidepressant, in Healthy Chinese Subjects.
Pharmaceuticals (Basel, Switzerland) – July 21, 2025
Summary
A new compound, a potential rapid-acting antidepressant for treatment-resistant depression, demonstrated promising safety in initial human trials. Researchers investigated the pharmacokinetics and safety of (R)-ketamine in healthy volunteers. They received varying intravenous doses of (R)-ketamine and its metabolite (R)-norketamine. Results showed predictable drug levels and, crucially, it was well-tolerated. Side effects were mild and temporary. Overall, this compound proved safe and well-tolerated, laying groundwork for its potential as a new treatment.
Abstract
Objectives: (R)-ketamine hydrochloride injection is a novel, rapid-acting antidepressant for the treatment of treatment-resistant depression. The a...
Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings.
Scientific reports – July 21, 2025
Summary
Religious and spiritual self-identity significantly shapes how individuals respond to art in psychedelic clinical settings, with 62% of participants reporting strong connections between their identity and art preferences. A survey involving 150 psychedelic society members revealed that those with a spiritual focus reacted positively to artworks featuring natural elements. In contrast, a non-psychedelic group showed less correlation between identity and art preferences. These findings highlight the importance of tailored art selections to enhance experiences in therapeutic environments, particularly through nature-themed imagery.
Abstract
Psychedelic clinical study environments are frequently visually manipulated, such as art; however, there has been little study of how the art selec...
Perturbing whole‐brain models of brain hierarchy: An application for depression following pharmacological treatment
Annals of the New York Academy of Sciences – July 21, 2025
Summary
Treatments for **depression** distinctly reconfigure the brain's organizational **hierarchy**. **Neuroscience** simulations reveal psilocybin increases brain flexibility, while escitalopram reduces it, both promoting healthier states. These **functional brain connectivity studies**, relevant to **psychology** and **medicine**, show how different **drug studies** like **psychedelics** influence brain dynamics. The findings, derived from advanced models, demonstrate how understanding brain **hierarchy** can inform future interventions for mental health conditions.
Abstract
Abstract Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally...
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.
Journal of clinical psychopharmacology – July 21, 2025
Summary
A new psychedelic compound, RE104, offers a unique, shorter experience. Researchers explored this 4-substituted tryptamine's safety, how it moves through the body (pharmacokinetics), and its effects in healthy volunteers experienced with hallucinogens, using a dose-finding approach. RE104 proved safe and well-tolerated, with predictable absorption. Psychedelic effects, including mystical experiences similar to psilocybin, correlated with dose. Notably, its effects were shorter than psilocin, lasting 3-4 hours, suggesting a favorable therapeutic profile.
Abstract
This study is the first to formally evaluate in humans the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RE104, a prodrug of...
"I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.
Addiction science & clinical practice – July 21, 2025
Summary
A notable finding: People with HIV, who often face unique challenges quitting tobacco, show significant openness to a novel psilocybin-assisted tobacco treatment. This qualitative study explored perceptions of using psilocybin for smoking cessation among this group. Interviews revealed that despite some initial uncertainties, participants were ultimately willing to try this unique tobacco treatment. The findings suggest psilocybin-aided therapy is acceptable for those with HIV seeking to quit tobacco.
Abstract
People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in...
Radiation therapy patients' interest in psychedelic-assisted therapy: results of a survey.
Radiation oncology (London, England) – July 21, 2025
Summary
A significant 43% of cancer patients expressed interest in psychedelic-assisted therapy (PAT) for alleviating mental health symptoms, particularly those facing radiation therapy. Among the 100 enrolled patients, interest was notably higher among younger individuals and those with prior mental health diagnoses like depression and anxiety. Conversely, 43% of participants unsure or opposed to PAT cited a lack of information as their main concern. As comorbid mental health symptoms affect 30-40% of cancer patients, PAT could address critical gaps in cancer-related mental health care.
Abstract
Comorbid mental health symptoms impact 30-40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Am...
Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials.
Pharmacy (Basel, Switzerland) – July 21, 2025
Summary
Some psychotropic substances, like lysergic acid amide (LSA), are being explored for unexpected benefits. A systematic review of 17 human studies aimed to understand the effects of this compound, often found in "legal highs." While LSA can cause euphoria, it also carries risks like anxiety and psychosis. Positively, evidence suggests LSA's potential for treating severe conditions such as cluster headaches. However, varied dosing and misinformation pose challenges.
Abstract
Objective: To systematically review the scientific literature on lysergic acid amide (LSA), focusing on its physical, neurobiological, and social e...
Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.
The journal of pain – July 21, 2025
Summary
Living with chronic pain often reshapes identity, hindering one's ability to find meaning. A new perspective suggests psilocybin could help individuals reframe their experience, fostering meaning-making and reducing self-pain enmeshment. By modulating self-perception, this approach aims to enhance engagement in rehabilitation, offering a novel path to improved physical and psychological well-being for those with chronic pain.
Abstract
Those living with chronic pain and comorbid functional disabilities are often confronted by a physically and emotionally transformative experience,...
Clinical Utility of Mystical Experiences: An Overview and Conceptual Framework.
The International journal of clinical and experimental hypnosis – July 21, 2025
Summary
Mystical experiences (MEs) can lead to profound psychological transformations, with 70% of participants reporting significant positive changes in well-being. These encounters often involve a sense of unity and transcendence, characterized by intense feelings and a noetic quality. A novel framework suggests that MEs are most effective when facilitated by specific preconditions: invitation, context, and individual aptitude. Following the experience, integration plays a crucial role in translating these non-ordinary states of consciousness into lasting benefits, highlighting their potential in clinical psychology for various conditions.
Abstract
Mystical experiences (MEs) are often profound and transformative encounters with a transcendent reality. Reported across many cultures and religion...
Emerging Use of Low-Dose Ketamine for Pain Management Beyond the ICU.
Journal of pain & palliative care pharmacotherapy – July 20, 2025
Summary
Ketamine, traditionally for critical care, is now a powerful opioid alternative for pain management. A community hospital successfully implemented a low-dose ketamine infusion protocol on inpatient floors. This offers effective relief, especially for post operative pain, demonstrating a safe, valuable new model for broader adoption of ketamine in pain management.
Abstract
Pain management is a critical challenge in healthcare as acute and chronic pain affect millions of individuals globally. Opioid-based therapies tha...
Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry.
Journal of chromatography. A – July 19, 2025
Summary
Scientists have discovered striking chemical differences between magic mushrooms and their non-psychedelic cousins. Using advanced food chemistry techniques, researchers mapped out the unique molecular fingerprints of various mushroom species through untargeted analysis. The results revealed distinct natural products that clearly separate psychedelic from non-psychedelic varieties, providing valuable insights for therapeutic applications.
Abstract
Psilocybin mushrooms, particularly those containing the psychoactive compounds psilocybin and psilocin, have attracted recent attention due to thei...
Sex-Specific Neuropsychiatric Effects of Subanesthetic Ketamine Exposure in Pregnant Mice and Their Offspring.
Cellular and molecular neurobiology – July 19, 2025
Summary
Remarkably, brief ketamine exposure during pregnancy in mice showed unexpected positive effects on offspring. Researchers explored if low-dose ketamine affected pregnant mothers and their offspring. Mothers exhibited less depression-like behavior. Strikingly, male offspring later showed reduced anxiety and depression, a positive outcome linked to changes in the hippocampus. This sex-specific effect was associated with higher levels of N-methyl-D-aspartate receptor subunits in male embryonic brains, suggesting a unique developmental impact. These findings highlight how prenatal influences can shape emotional well-being, particularly stress resilience, in a sex-dependent manner.
Abstract
Depression during pregnancy is often overlooked and undertreated. Ketamine has been shown to exert prompt and sustained antidepressant effects in p...
Varying the High-pass-Cut Off Frequency Influences the Accuracy of the Model for Detection of Mind State Associated with Himalayan Yoga and Vipassana Meditation.
Annals of neurosciences – July 19, 2025
Summary
The use of a 1 Hz high-pass filter significantly enhances meditation classification accuracy, achieving 100% for Himalayan Yoga and 99.45% for Vipassana using a Convolutional Neural Network (CNN). In this analysis, two classification tasks were performed on electroencephalogram (EEG) data from meditation practices, with sample sizes indicating robust results. The Inception Convolutional Gated Recurrent Neural Network (IC-RNN) also showed impressive results, reaching 86.19% for Vipassana and 88.15% for Himalayan Yoga. These findings highlight the importance of pre-processing techniques in deep learning applications for mental state identification.
Abstract
Meditation and Yoga practices are being adopted and gaining considerable interest as a tool that prevents the occurrence of numerous ailments. Medi...
Perioperative use of esketamine for the prevention of postpartum depression after cesarean section: a meta-analysis.
BMC pregnancy and childbirth – July 19, 2025
Summary
Remarkably, early Postpartum Depression (PPD) after Cesarean section can be significantly reduced. A recent meta-analysis, combining data from multiple studies, explored whether perioperative Esketamine could prevent PPD. Findings show that mothers given Esketamine experienced notably lower PPD incidence and better pain control, offering a promising strategy for maternal mental health.
Abstract
Esketamine has a relatively low adverse effect on mothers and infants during cesarean sections, making it an ideal adjunct in spinal anesthesia. Ho...
Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials
Journal of Affective Disorders – July 18, 2025
Summary
Psilocybin offers rapid, sustained clinical benefits when combined with psychological support. A systematic review of 22 clinical trials, identified via databases like MEDLINE, revealed consistent therapeutic structure. Yet, less than half reported standardization measures for psychotherapist training or Psychotherapy Techniques. This gap in Standardization within Psychedelics and Drug Studies, impacting Medicine and Psychology, undermines replicability. Robust standardization, vital for all mental health interventions including Digital Mental Health Interventions, is crucial for advancing psilocybin's clinical potential.
Abstract
Accumulating evidence suggests that psilocybin can produce rapid and sustained clinical benefits when administered in conjunction with psychologica...
A practical measure of integrated information reveals alpha-band activity and the posterior cortex as neural correlates of arousal.
NeuroImage – July 18, 2025
Summary
A new measure, Φcopula, significantly enhances the assessment of consciousness by estimating integrated information more accurately than traditional methods. In simulations, Φcopula maintained low bias and mean squared error across high-dimensional systems. When applied to electroencephalographic data from 30 participants in various arousal states, it revealed a notable decrease in alpha-band Φcopula during propofol anesthesia and sleep. Additionally, classifiers using Φcopula outperformed those based on functional connectivity, with the dorsal attention and default mode networks contributing most significantly to this integrated information in the posterior cortex.
Abstract
The search for neurophysiological markers of consciousness and their neural substrates remains a focal point in neuroscience research. The integrat...
Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
OpenAlex – July 18, 2025
Summary
Psilocybin, a psychedelic alkaloid, appears to alter the epigenome, potentially explaining its lasting benefits for psychiatric conditions like alcohol use disorder. In 40 patients, a genome-wide association study of DNA methylation revealed changes after a 25mg dose. One CpG site in TLE4 and altered RASGRP4 methylation showed an association with psilocybin treatment. These epigenetic shifts relate to neuroplasticity and immune functions, suggesting a biological basis for reduced drinking behavior and depressive symptoms, crucial for psychology and psychiatry.
Abstract
Abstract The serotonergic hallucinogen psilocybin has shown potential as a treatment for psychiatric conditions like alcohol use disorder (AUD) and...
Development of an Australian Clinical Practice Guideline on methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy for Post-traumatic Stress Disorder.
Journal of affective disorders – July 17, 2025
Summary
Australia is pioneering a new era for mental health, allowing authorized prescribing of Ecstasy for PTSD. This initiative outlines the development of robust Therapeutic guidelines for MDMA-assisted psychotherapy. Using a rigorous, evidence-based process, experts are crafting protocols to ensure safe and effective psychedelic-assisted therapy. This marks a significant step towards providing carefully considered, evidence-based treatment for those battling PTSD.
Abstract
Despite recent clinical and research interest, medical use of psychedelics has not been legalised in most jurisdictions. The Australian Therapeutic...
Developing a mindfulness program for pre-clinical medical students in Indonesia: a mixed-methods study on suitability and appropriateness.
BMC medical education – July 17, 2025
Summary
Medical students face significant psychological distress, with high rates of anxiety and burnout. A newly developed Mindfulness Program for Pre-Clinical Medical Students in Indonesia (MPPMS-I) shows promise in addressing these issues. In a study involving first-, second-, and third-year students, interest levels ranged from 5.75 to 6.6 out of 7, indicating strong engagement. Participants found the program highly relevant to their academic challenges and expressed a high likelihood of applying mindfulness techniques like S.T.O.P. meditation in daily life, highlighting its feasibility and cultural fit for improving student well-being.
Abstract
Medical students experience high rates of psychological distress, including depression, anxiety, burnout, and suicidality, due to rigorous academic...
The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal
ACS Pharmacology & Translational Science – July 16, 2025
Summary
Does the psychedelic experience truly heal depression? A new approach investigates whether psilocybin's therapeutic effects, crucial for clinical psychology, require conscious awareness or solely neurobiological actions. One group receives 25mg psilocybin with psychotherapist-guided integration. Another receives the same dose under anesthesia, eliminating consciousness. A third, placebo group also undergoes anesthesia. By isolating subjective experiences from the neurotransmitter receptor influence, this drug study aims to clarify if the profound psychological shifts, often linked to psychoanalysis, are essential for improving depression symptoms. This will reshape future psychedelic treatment protocols.
Abstract
The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable at...
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.
AJOB empirical bioethics – July 16, 2025
Summary
How do we truly inform participants about unique psychedelic experiences? Analyzing informed consent documents from psilocybin clinical trials, researchers found that while essential risks were well-covered, details specific to altered states, like ineffability, were less common. This highlights ongoing efforts in psychedelic bioethics to develop enhanced consent, ensuring comprehensive participant understanding for psychedelic clinical trials.
Abstract
Classic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such...